Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000730 · ClinicalTrials.gov registry record · Phase 3
Comparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
NCT00000730: Clinical Trial Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00000730 is a Phase 3 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 240 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000730, a Phase 3 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
Study Summary
This study compares three different therapies for treatment of refractory Pneumocystis carinii pneumonia (PCP) in patients with AIDS. "Refractory" means that the patient has failed to respond to at least 4 days of treatment with either of two standard therapies: (1) sulfamethoxazole/trimethoprim (SMX/TMP) or (2) pentamidine (PEN). This study compares therapy with trimetrexate (TMTX) and leucovorin (LCV) to standard therapy and standard therapy plus high-dose steroids (methylprednisolone). The purpose is to find better and safer forms of treatment for PCP in AIDS patients. There is at present no scientific information about the best treatment for an AIDS patient with PCP who is not improving while receiving the standard therapies (SMX/TMP or PEN). New drug treatments are available, including steroid therapy and TMTX, but there is no information proving that these new treatments work better than the standard therapies.
Interventions
- DRUG Methylprednisolone
- DRUG Leucovorin calcium
- DRUG Pentamidine isethionate
- DRUG Sulfamethoxazole-Trimethoprim
- DRUG Trimetrexate glucuronate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Est. Completion | 1989-03 |
| Phase | Phase 3 |
Why NCT00000730 stopped before completion
NCT00000730 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 5 interventions - of which Methylprednisolone is the first listed.
NCT00000730 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00000730 about?
NCT00000730 is a clinical study titled "Comparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients". This study compares three different therapies for treatment of refractory Pneumocystis carinii pneumonia (PCP) in patients with AIDS. "Refractory" means that the patient has failed to respond to at least 4 days of treatment with either of two standard therapies: (1) sulfamethoxazole/trimethoprim (SM...
What is the current status of trial NCT00000730?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 240 participants. Estimated completion is 1989-03.
What interventions are being tested in trial NCT00000730?
The interventions under investigation include: Methylprednisolone (DRUG), Leucovorin calcium (DRUG), Pentamidine isethionate (DRUG), Sulfamethoxazole-Trimethoprim (DRUG), Trimetrexate glucuronate (DRUG).
Who is sponsoring clinical trial NCT00000730?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00000730's enrollment target sits among peer trials
240 1273rd of 2000 higher than 710 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence